224 related articles for article (PubMed ID: 27586806)
1. Sjögren's syndrome: from pathogenesis to novel therapeutic targets.
Barone F; Colafrancesco S
Clin Exp Rheumatol; 2016; 34(4 Suppl 98):58-62. PubMed ID: 27586806
[TBL] [Abstract][Full Text] [Related]
2. Phosphatidylinositol 3-kinase delta pathway: a novel therapeutic target for Sjögren's syndrome.
Nayar S; Campos J; Smith CG; Iannizzotto V; Gardner DH; Colafrancesco S; Pipi E; Kollert F; Hunter KJ; Brewer C; Buckley CD; Bowman SJ; Priori R; Valesini G; Juarez M; Fahy WA; Fisher BA; Payne A; Allen RA; Barone F
Ann Rheum Dis; 2019 Feb; 78(2):249-260. PubMed ID: 30472652
[TBL] [Abstract][Full Text] [Related]
3. Interferon-β inhibits inflammatory responses mediators via suppression of iNOS signaling pathway in PBMCs from patients with primary Sjögren's syndrome.
Benchabane S; Belkhelfa M; Belguendouz H; Zidi S; Boudjelida A; Youinou P; Touil-Boukoffa C
Inflammopharmacology; 2018 Oct; 26(5):1165-1174. PubMed ID: 29869303
[TBL] [Abstract][Full Text] [Related]
4. Bufotalin ameliorates experimental Sjögren's syndrome development by inhibiting Th17 generation.
Huang Y; Yang G; Fei J; Wu Y; Yan J
Naunyn Schmiedebergs Arch Pharmacol; 2020 Oct; 393(10):1977-1985. PubMed ID: 31950221
[TBL] [Abstract][Full Text] [Related]
5. Cytokines in Sjögren's syndrome.
Roescher N; Tak PP; Illei GG
Oral Dis; 2009 Nov; 15(8):519-26. PubMed ID: 19519622
[TBL] [Abstract][Full Text] [Related]
6. [Indications and options of new immune modulatory therapies for Sjögren's syndrome].
Feist E; Dörner T; Hansen A
Z Rheumatol; 2007 Dec; 66(8):679-85. PubMed ID: 17999070
[TBL] [Abstract][Full Text] [Related]
7. CD8
Zhou H; Yang J; Tian J; Wang S
Front Immunol; 2020; 11():602823. PubMed ID: 33584670
[TBL] [Abstract][Full Text] [Related]
8. Alleviating effect of paeoniflorin-6'-O-benzene sulfonate in antigen-induced experimental Sjögren's syndrome by modulating B lymphocyte migration via CXCR5-GRK2-ERK/p38 signaling pathway.
Chen X; Zhang P; Liu Q; Zhang Q; Gu F; Xu S; Körner H; Wu H; Wei W
Int Immunopharmacol; 2020 Mar; 80():106199. PubMed ID: 31955068
[TBL] [Abstract][Full Text] [Related]
9. Primary Sjogren's syndrome and autoimmune cytopenias: a relation often overlooked.
Khattri S; Barland P
Bull NYU Hosp Jt Dis; 2012; 70(2):130-2. PubMed ID: 22892005
[TBL] [Abstract][Full Text] [Related]
10. Pro-inflammatory cytokines enhance ERAD and ATF6α pathway activity in salivary glands of Sjögren's syndrome patients.
Barrera MJ; Aguilera S; Castro I; Cortés J; Bahamondes V; Quest AFG; Molina C; González S; Hermoso M; Urzúa U; Leyton C; González MJ
J Autoimmun; 2016 Dec; 75():68-81. PubMed ID: 27461470
[TBL] [Abstract][Full Text] [Related]
11. Increased mTORC1 activation in salivary gland B cells and T cells from patients with Sjögren's syndrome: mTOR inhibition as a novel therapeutic strategy to halt immunopathology?
Blokland SLM; Hillen MR; Wichers CGK; Zimmermann M; Kruize AA; Radstake TRDJ; Broen JCA; van Roon JAG
RMD Open; 2019; 5(1):e000701. PubMed ID: 30713717
[No Abstract] [Full Text] [Related]
12. Co-culture system of human salivary gland epithelial cells and immune cells from primary Sjögren's syndrome patients: an in vitro approach to study the effects of Rituximab on the activation of the Raf-1/ERK1/2 pathway.
Lisi S; Sisto M; D'Amore M; Lofrumento DD
Int Immunol; 2015 Apr; 27(4):183-94. PubMed ID: 25381666
[TBL] [Abstract][Full Text] [Related]
13. Salivary gland secretome: a novel tool towards molecular stratification of patients with primary Sjögren's syndrome and non-autoimmune sicca.
Blokland SLM; Hillen MR; van Vliet-Moret FM; Bikker A; de Jager W; Pandit A; Kruize AA; Radstake TRDJ; van Roon JAG
RMD Open; 2019; 5(1):e000772. PubMed ID: 30713719
[TBL] [Abstract][Full Text] [Related]
14. Catalpol ameliorates Sjögren's Syndrome by modulating interplay of T and B cells.
Lin R; Hao D; Dong Y; Wang Y
Biomed Pharmacother; 2020 Mar; 123():109806. PubMed ID: 31951976
[TBL] [Abstract][Full Text] [Related]
15. One year in review 2015: Sjögren's syndrome.
Luciano N; Valentini V; Calabrò A; Elefante E; Vitale A; Baldini C; Bartoloni E
Clin Exp Rheumatol; 2015; 33(2):259-71. PubMed ID: 25896475
[TBL] [Abstract][Full Text] [Related]
16. Expression of BAFF (BLyS) in T cells infiltrating labial salivary glands from patients with Sjögren's syndrome.
Lavie F; Miceli-Richard C; Quillard J; Roux S; Leclerc P; Mariette X
J Pathol; 2004 Apr; 202(4):496-502. PubMed ID: 15095277
[TBL] [Abstract][Full Text] [Related]
17. Targeting primary Sjögren's syndrome.
Odani T; Chiorini JA
Mod Rheumatol; 2019 Jan; 29(1):70-86. PubMed ID: 30424703
[TBL] [Abstract][Full Text] [Related]
18. Autoimmune hepatitis in primary Sjogren's syndrome: pathological study of the livers and labial salivary glands in 17 patients with primary Sjogren's syndrome.
Matsumoto T; Morizane T; Aoki Y; Yamasaki S; Nakajima M; Enomoto N; Kobayashi S; Hashimoto H
Pathol Int; 2005 Feb; 55(2):70-6. PubMed ID: 15693852
[TBL] [Abstract][Full Text] [Related]
19. The Role of Interferons in the Pathogenesis of Sjögren's Syndrome and Future Therapeutic Perspectives.
Del Papa N; Minniti A; Lorini M; Carbonelli V; Maglione W; Pignataro F; Montano N; Caporali R; Vitali C
Biomolecules; 2021 Feb; 11(2):. PubMed ID: 33572487
[TBL] [Abstract][Full Text] [Related]
20. Identification of IL-18 and Th17 cells in salivary glands of patients with Sjögren's syndrome, and amplification of IL-17-mediated secretion of inflammatory cytokines from salivary gland cells by IL-18.
Sakai A; Sugawara Y; Kuroishi T; Sasano T; Sugawara S
J Immunol; 2008 Aug; 181(4):2898-906. PubMed ID: 18684981
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
